Renovo Group plc is a biopharmaceutical product company. As of September 30, 2011, the Company had an ongoing clinical trial, Prevascar, for improving the appearance of scarring in the skin. On May 26, 2011, the Company announced that the data from the Prevascar proof of concept clinical trial involving 1centimeter skin incisions in volunteers of African Ancestral Group origin showed a significant improvement in scar width (p=0.03) of approximately 12% one month post-wounding, as measured from histological sections of the excised scars. The differences were significant for one of the four doses of Prevascar tested against placebo. During the fiscal year ended September 30, 2011, all of the Company�s other pipeline activities were ceased.